Research by Dr. Anan et coll. on urolithiasis treatment using medical big data received the Japan Urolithiasis Society Award
- September 8, 2023
Medical Data Vision (MDV) Co., Ltd. (Chiyoda-ku, Tokyo, President: Hiroyuki Iwasaki), operating the largest database of medical data in Japan, is proud to announce that Dr. Tsuyoshi ANAN, Tohoku Medical and Pharmaceutical University School of Medicine Urology Department (currently Yotsuya Medical Cube Urology Department Head), as well as Professor Takuo Hirose, Endowed Course for Integrative Renal Failure Medicine/Tohoku University Graduate School of Medicine Assistant, and Deputy Chief Pharmacist Daisuke Kikuchi at Tohoku Medical and Pharmaceutical University Hospital Pharmacy Department received the 2023 Society Award from the Japanese Society for Urolithiasis for their research paper* partly based on MDV Data.
This study is the first in the world to confirm the effect of antidiabetic drugs (SGLT2 inhibitors) on the formation of kidney stones. Epidemiological studies have shown that SGLT2 inhibitors reduce the incidence of urinary stones in Japanese male diabetic patients. Animal and cell experiments have revealed that SGLT2 inhibition suppresses kidney stone formation, and that the mechanism involves an inflammatory response. The results show that this may be a promising treatment approach for kidney stone. This research originality lies in the use of MDV largest scale medical data.
* Tohoku Medical and Pharmaceutical University Press Release] New possibilities for anti-diabetic drugs (SGLT2 inhibitors) - Verifying the possibility of anti-diabetic drugs (SGLT2 inhibitors) in suppressing urinary tract stones using large-scale epidemiological data on Japanese subjects -
Academic award certificate
Picture: Dr. Anan provided by
Yotsuya Medical Cube
Every year, only one study published in the previous year will receive the Japan Urolithiasis Society’s Society Award. Upon receiving the award, Dr. Anan commented as follows:
“I am very happy to have received the prestigious award from the Japan Urolithiasis Society. This research was a joint research with doctors from the Department of Nephrology and Pharmacy and was conducted on a diabetes treatment drug. We investigated whether SGLT2 inhibitors, which are attracting attention for their cardio- and renal protective functions, can suppress kidney stone formation through their anti-inflammatory effects using real-world data, animal and cell research. I would like to conduct clinical research to see if it can lead to prevention and treatment of urinary tract stones and move forward so that we can deliver therapeutic drugs to actual clinical sites.”
“Renal stone formation mechanism by SGLT2 inhibition” abstract from the paper